PT  - JOURNAL ARTICLE
AU  - MORITA, MASARU
AU  - EGASHIRA, AKINORI
AU  - NAKAJI, YU
AU  - KAGAWA, MASAKI
AU  - SUGIYAMA, MASAHIKO
AU  - YOSHIDA, DAISUKE
AU  - OTA, MITSUHIKO
AU  - IKEBE, MASAHIKO
AU  - MASUDA, MUNEYUKI
AU  - INOUE, YOJIRO
AU  - KUNITAKE, NAONOBU
AU  - TOH, YASUSHI
TI  - Treatment of Squamous Cell Carcinoma of the Esophagus Synchronously Associated with Head and Neck Cancer
DP  - 2017 Sep 01
TA  - In Vivo
PG  - 909--916
VI  - 31
IP  - 5
4099  - http://iv.iiarjournals.org/content/31/5/909.short
4100  - http://iv.iiarjournals.org/content/31/5/909.full
SO  - In Vivo2017 Sep 01; 31
AB  - Background/Aim: The aim of this study was to clarify the treatment strategy for synchronous squamous cell carcinoma of the esophagus (ESCC) and head and neck cancer (HNC). Patients and Methods: Treatment outcomes of 91 patients with synchronous ESCC and HNC were evaluated. Thirty-eight patients received simultaneous definitive chemoradiotherapy (CRT) and 15 patients underwent simultaneous resection. Results: Among the patients who received simultaneous CRT, adverse events (grade 3-5) were recognized in 14 patients (40%), including one case of death due to aspiration pneumonia. Complete response was observed in 22 patients with ESCC (58%) and 19 patients with HNC (50%). The five-year survival rate was 44%. There were no in-hospital deaths after simultaneous resection; however, postoperative complications were recognized in 4 patients. The five-year OS was 70%. Conclusion: The treatment of synchronous ESCC and HNC must be decided by adopting a strategy that is appropriate for each case. Both simultaneous CRT and simultaneous resection are feasible and effective treatment options.